T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins

Yixiang Xu; Georgina To'a Salazar; Ningyan Zhang; Zhiqiang An

doi:10.1093/abt/tbz001

T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins

Antib Ther. 2019 Jan 21;2(1):22-32. doi: 10.1093/abt/tbz001. eCollection 2019 Jan.

Authors

Yixiang Xu¹, Georgina To'a Salazar¹, Ningyan Zhang¹, Zhiqiang An¹

Affiliation

¹ Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Abstract

T-cell receptor mimic (TCRm) antibodies combine the capacity of a T cell to target intracellular antigens with other capacities unique to antibodies. Neoantigens are abnormal proteins that arise as a consequence of somatic mutations. Technological advances promote the development of neoantigen-targeting therapies including TCRm antibody therapies. This review summarizes key characteristics of TCRm antibodies, in particular those targeting neoantigens, and further introduces discussion of obstacles that must be overcome to advance TCRm therapeutics.

Keywords: CAR-T cell therapy; TCR receptor mimic antibody; bispecific antibody T cell engager; cancer testis antigen (CTA); neoantigen.

Publication types

Review